CoLucid Pharmaceuticals to Present at Two Investor Conferences in September

CAMBRIDGE, Mass., Sept. 3, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that Thomas P. Mathers, Chief Executive Officer, will provide a corporate overview at two investor conferences in September.

Rodman & Renshaw 17th Annual Global Investment Conference
Date: Thursday, September 10
Time: 11:15am Eastern Time
Location: St. Regis Hotel, Library Room (2nd Floor)
New York City
Ladenburg Thalmann 2015 Healthcare Conference
Date: Tuesday, September 29
Time: 9:30am Eastern Time
Location: Sofitel New York Hotel, Odeon room
New York City
Webcast: The presentation will be webcast live on CoLucid's Investor Relations website at http://www.colucid.com/investor_relations

About CoLucid Pharmaceuticals, Inc.

CoLucid was founded in 2005 and is developing oral lasmiditan for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings.

CONTACT: Thomas Mathers Chief Executive Officer CoLucid Pharmaceuticals, Inc. (781) 365-2596 Hans Vitzthum Managing Director LifeSci Advisors, LLC. (212) 915-2568Source:CoLucid Pharmaceuticals, Inc